← Product Code [ITX](/submissions/RA/subpart-b%E2%80%94diagnostic-devices/ITX) · K964549 # ALOKA UST-5258-5 DIAGNOSTIC ULTRASOUND TRANSDUCER (K964549) _Aloka Co., Ltd. · ITX · Jun 3, 1997 · Radiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/RA/subpart-b%E2%80%94diagnostic-devices/ITX/K964549 ## Device Facts - **Applicant:** Aloka Co., Ltd. - **Product Code:** [ITX](/submissions/RA/subpart-b%E2%80%94diagnostic-devices/ITX.md) - **Decision Date:** Jun 3, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 892.1570 - **Device Class:** Class 2 - **Review Panel:** Radiology ## Indications for Use Diagnostic ultrasound imaging and Doppler analysis of the human body. Medical disciplines that use transesophageal diagnostic ultrasound include Cardiology, Surgery and Trauma. ## Device Story Aloka UST-5258-5 is a diagnostic ultrasound transducer. It transmits high-frequency sound waves into the body via a piezo-electric element; reflected energy, based on tissue acoustic impedance, is captured and transmitted via cable to a system console (SSD-1700). The device supports B-mode, M-mode, Pulsed Wave Doppler (PWD), and Color Flow Mapping (CFM) to visualize anatomy and blood flow. Operated by clinicians in cardiology, surgery, or trauma settings. Output is a processed ultrasound image displayed on the console, used by physicians to aid in diagnosis of disease or abnormality. ## Clinical Evidence Bench testing only. No clinical data provided. Substantial equivalence is based on technological comparison, acoustic power output measurements, and compliance with electrical and physical safety standards. ## Technological Characteristics Piezo-electric ultrasound transducer. Supports B-mode, M-mode, PWD, and CFM. Patient contact materials evaluated for safety. Complies with electrical and physical safety standards. Acoustic power output levels are within FDA-allowed limits. Designed for use with the SSD-1700 system. ## Regulatory Identification A diagnostic ultrasonic transducer is a device made of a piezoelectric material that converts electrical signals into acoustic signals and acoustic signals into electrical signals and intended for use in diagnostic ultrasonic medical devices. Accessories of this generic type of device may include transmission media for acoustically coupling the transducer to the body surface, such as acoustic gel, paste, or a flexible fluid container. ## Predicate Devices - Aloka UST-5228-5 diagnostic ultrasound transducer ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} JUN - 3 1997 1. 510(k) SUMMARY K964549 This summary statement complies with 21 CFR, section 807.92 as amended March 14, 1995. This premarket notification has been submitted by Aloka Co., Ltd. and covers the Aloka UST-5258-5 diagnostic ultrasound transducer. The address is: 10 Fairfield Boulevard Wallingford, CT 06492 The contact person is Paul D. Smolenski, Manager, Quality and Regulatory Affairs. The proprietary name is the Aloka UST-5258-5 diagnostic ultrasound transducer. The common name for this type of device is a diagnostic ultrasound transducer. The item in this submission is covered under the following classification: 90 ITX - Transducer, Ultrasonic, Diagnostic The above as stated in 21 CFR, part 892.1570, has been classified as regulatory Class II. The Aloka UST-5258-5 is substantially equivalent to the Aloka UST-5228-5 diagnostic ultrasound transducer. The Aloka UST-5258-5 functions in the same manner as other diagnostic ultrasound devices. High frequency sound waves are transmitted into the body by a piezo-electric transducer. In the body, differences in the acoustic impedance of different tissues reflect a certain amount of the ultrasound energy back to the transducer, where it is transmitted via the probe cable to the system console and processed into an image. The Aloka UST-5258-5 transducer can also use the Doppler shift of sound reflected from moving tissues (blood) to detect and display flow. The Aloka UST-5258-5, like other marketed diagnostic ultrasound transducers, is indicated for imaging body structures to aid in the diagnosis of disease or abnormality. The Aloka UST-5258-5 diagnostic ultrasound transducer is similar in technological characteristics to ultrasound transducers marketed by Aloka and others: - The UST-5258-5 is indicated for the same diagnostic ultrasound applications as other products currently marketed by Aloka and others. {1} - The UST-5258-5 has the same gray-scale and Doppler abilities as other products currently offered by Aloka and others. - The UST-5258-5 uses essentially the same technologies for imaging, Doppler functions and signal processing as other products currently marketed by Aloka and others. - The UST-5258-5 has the same method of use as other products currently marketed by Aloka and others. - The UST-5258-5 acoustic power output levels are below the maximum levels allowed by the FDA. - The UST-5258-5 is subjected to the same Quality Assurance systems in development and production as other products currently marketed by Aloka. - The patient contact materials used in the UST-5258-5 have been evaluated for safety via the same standards and methods as other products marketed by Aloka and others. These materials have been found to be safe for the intended uses. - The UST-5258-5 complies with the same electrical and physical safety standards as other products currently marketed by Aloka and others. {2} DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 JUN - 3 1997 Paul D. Smolenski Manager, Quality and Regulatory Affairs Aloka Company, LTD. 10 Fairfield Blvd. Wallingford, CT 06492-7502 Re: K964549 ALOKA UST-5258 Diagnostic Ultrasound Transducer Dated: March 12, 1997 Received: March 13, 1997 Regulatory Class: II 21 CFR 892.1570/Procode: 90 ITX Dear Mr. Smolenski: We have reviewed your section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug and Cosmetic Act. You may, therefore, market the device, subject to the general controls provisions Act (Act). The general controls provisions of the Act include requirements for registration, listing of devices, good manufacturing practices, labeling, and prohibitions against misbranding and adulteration. This determination of substantial equivalence applies to the following transducer intended for use with the SSD-1700 as described in your premarket notification: **Transducer Model Number** 5 MHZ UST-5258 If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval) it may be subject to such additional controls. Existing major regulations affecting your device can be found in the *Code of Federal Regulations*, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the FDA will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, the Food and Drug Administration (FDA) may publish further announcements concerning your device in the *Federal Register*. *Please note*: this response to your premarket notification does not affect any obligation you may have under sections 531 and 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market. {3} Page 2 - Mr. Paul Smolenski If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597 or at its Internet address “http://www.fda.gov/cdrh/dsmamain.html”. If you have any questions regarding the content of this letter, please contact Maureen Butler at (301) 594-1212. Sincerely yours, Lillian Yin, Ph.D. Director, Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health {4} # Indications for Use Summary Device Name: Aloka UST-5258-5 Diagnostic Ultrasound Transducer 510(k) Number: Unknown at time of submission Intended Use: Diagnostic ultrasound imaging and Doppler analysis of the human body. Medical disciplines that use transesophageal diagnostic ultrasound include Cardiology, Surgery and Trauma. | Clinical Applications | Modes of Operation | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | A | B | M | PWD | CWD | Color Flow Mapping | Combined | Other | | Ophthalmic | | | | | | | | | | Fetal | | | | | | | | | | Abdominal | | | | | | | | | | Small Organ | | | | | | | | | | Cardiac | | ☑ | ☑ | ☑ | | ☑ | B/M, B/PWD, M/CFM, B/CFM/PWD | | | Peripheral Vessel | | | | | | | | | | Other* | | ☑ | ☑ | ☑ | | ☑ | B/M, B/PWD, M/CFM, B/CFM/PWD | | *Intraoperative, Trauma. David C. Segerman (Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices 510(k) Number 15964549 Prescription Use ☑ (Per 21 CFR 801.109) --- **Source:** [https://fda.innolitics.com/submissions/RA/subpart-b%E2%80%94diagnostic-devices/ITX/K964549](https://fda.innolitics.com/submissions/RA/subpart-b%E2%80%94diagnostic-devices/ITX/K964549) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com